This study is testing an injectable solution called SL1002 to see if it can safely and effectively reduce knee pain caused by osteoarthritis. You might be able to join if you are at least 40 years old, have chronic knee pain from mild to moderate osteoarthritis, and meet other health requirements like certain Body Mass Index (BMI) limits. The researchers will compare SL1002 to normal saline (a placebo) to see if SL1002 helps reduce your average daily pain intensity while walking over 12 weeks. The study aims to enroll 150 participants, but its current recruitment status is unclear.

Study design

This is a randomized, double-blind, placebo-controlled study, meaning participants are randomly assigned to receive either SL1002 or normal saline, and neither you nor your doctor will know which you are receiving. It is designed to assess the safety and effectiveness of a single dose.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The main goal is to measure changes in pain from when you start the study until Week 12.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.